Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast-Reference-Cited by-同舟云学术

Fluorescence In Situ Hybridization (FISH) as Primary Methodology for the Assessment of HER2 Status in Adenocarcinoma of the Breast

Published:2007-12 Issue:4 Volume:16 Page:207-210
ISSN:1052-9551
Container-title:Diagnostic Molecular Pathology
language:en
Short-container-title:Diagnostic Molecular Pathology

Author:

Tubbs Raymond R.,Hicks David G.,Cook James,Downs-Kelly Erinn,Pettay James,Hartke Mary Beth,Hood LaShonda,Neelon Rosemary,Myles Jonathan,Budd George Thomas,Moore Halle C.,Andresen Steve,Crowe Joseph P.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cell Biology,Molecular Biology,Pathology and Forensic Medicine

Reference30 articles.

1. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use

2. Comparison of Immunohistochemical and Fluorescence In Situ Hybridization Assessment of HER-2 Status in Routine Practice

3. Correlation between immunohistochemistry (HercepTest) and fluorescencein situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres

4. Comparison of HER2 Status by Fluorescence in Situ Hybridization and Immunohistochemistry to Predict Benefit From Dose Escalation of Adjuvant Doxorubicin-Based Therapy in Node-Positive Breast Cancer Patients

Cited by 71 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimized biomarker evaluation and molecular testing in the era of breast cancer precision medicine;Biotechnic & Histochemistry;2024-09-11

2. Detection of ERBB2 and CEN17 signals in fluorescent in situ hybridization and dual in situ hybridization for guiding breast cancer HER2 target therapy;Artificial Intelligence in Medicine;2023-07

3. Update on prognostic and predictive biomarkers of breast cancer;Seminars in Diagnostic Pathology;2022-09

4. Avoiding “False Positive” and “False Negative” Immunohistochemical Results in Breast Pathology;Pathobiology;2022

5. HER2 in situ hybridization test in breast cancer: quantifying margins of error and genetic heterogeneity;Modern Pathology;2021-05-12